Literature DB >> 25474078

Assessment of airway microbiota and inflammation in cystic fibrosis using multiple sampling methods.

Edith T Zemanick1, Brandie D Wagner, Charles E Robertson, Mark J Stevens, Stanley J Szefler, Frank J Accurso, Scott D Sagel, J Kirk Harris.   

Abstract

RATIONALE: Oropharyngeal (OP) swabs and induced sputum (IS) are used for airway bacteria surveillance in nonexpectorating children with cystic fibrosis (CF). Molecular analyses of these airway samples detect complex microbial communities. However, the optimal noninvasive sampling approach for microbiota analyses and the clinical relevance of microbiota, particularly its relationship to airway inflammation, is not well characterized.
OBJECTIVES: The goals of this study were to compare molecular analyses of concurrently collected saliva, OP swabs, IS, and expectorated sputum (ES) from children with CF and to determine the association between microbiota, lung function, and airway inflammation.
METHODS: Saliva, OP swabs, IS, and ES were collected from 16 children with CF. Spirometry was performed.
MEASUREMENTS AND MAIN RESULTS: Respiratory and saliva samples (n = 61) were sequenced for bacterial microbial communities, and total and CF-specific bacterial quantitative PCR assays were performed. Airway samples underwent conventional culture for CF-specific pathogens. Neutrophil elastase, IL-1β, IL-1ra, IL-6, Il-8, TNF-α, and vascular endothelial growth factor were measured in ES and IS. Sequencing results from individual subjects were similar across samples, with greater between-subject than within-subject variation. However, Pseudomonas and Staphylococcus were detected in higher relative abundance from lower airways (ES and IS) compared with paired upper airway samples (OP and saliva). Pseudomonas, Staphylococcus, and Enterobacteriaceae correlated with increased airway inflammation. Divergence between microbiota in upper airway compared with lower airway samples, indicating greater differences between communities, was associated with increased sputum neutrophil elastase.
CONCLUSIONS: Bacteria detected in IS samples resemble ES samples, whereas OP samples may underrepresent bacteria associated with airway inflammation. Divergence of lower airway communities from upper airway was associated with airway inflammation and may portend disease progression.

Entities:  

Keywords:  DNA sequencing; bacterial infection; microbiome; oropharyngeal swab; sputum

Mesh:

Substances:

Year:  2015        PMID: 25474078      PMCID: PMC4342834          DOI: 10.1513/AnnalsATS.201407-310OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  47 in total

1.  Univariate statistical analysis of environmental (compositional) data: problems and possibilities.

Authors:  Peter Filzmoser; Karel Hron; Clemens Reimann
Journal:  Sci Total Environ       Date:  2009-09-08       Impact factor: 7.963

2.  Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis.

Authors:  D S Armstrong; K Grimwood; J B Carlin; R Carzino; A Olinsky; P D Phelan
Journal:  Pediatr Pulmonol       Date:  1996-05

3.  Airway inflammation in children with cystic fibrosis and healthy children assessed by sputum induction.

Authors:  S D Sagel; R Kapsner; I Osberg; M K Sontag; F J Accurso
Journal:  Am J Respir Crit Care Med       Date:  2001-10-15       Impact factor: 21.405

4.  Prospective evaluation of emerging bacteria in cystic fibrosis.

Authors:  G Steinkamp; B Wiedemann; E Rietschel; A Krahl; J Gielen; H Bärmeier; F Ratjen
Journal:  J Cyst Fibros       Date:  2005-03       Impact factor: 5.482

5.  Airway microbiota and pathogen abundance in age-stratified cystic fibrosis patients.

Authors:  Michael J Cox; Martin Allgaier; Byron Taylor; Marshall S Baek; Yvonne J Huang; Rebecca A Daly; Ulas Karaoz; Gary L Andersen; Ronald Brown; Kei E Fujimura; Brian Wu; Diem Tran; Jonathan Koff; Mary Ellen Kleinhenz; Dennis Nielson; Eoin L Brodie; Susan V Lynch
Journal:  PLoS One       Date:  2010-06-23       Impact factor: 3.240

6.  Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis.

Authors:  Michael M Tunney; Tyler R Field; Thomas F Moriarty; Sheila Patrick; Gerd Doering; Marianne S Muhlebach; Matthew C Wolfgang; Richard Boucher; Deirdre F Gilpin; Andrew McDowell; J Stuart Elborn
Journal:  Am J Respir Crit Care Med       Date:  2008-02-08       Impact factor: 21.405

7.  Reliability of quantitative real-time PCR for bacterial detection in cystic fibrosis airway specimens.

Authors:  Edith T Zemanick; Brandie D Wagner; Scott D Sagel; Mark J Stevens; Frank J Accurso; J Kirk Harris
Journal:  PLoS One       Date:  2010-11-30       Impact factor: 3.240

8.  Nurture trumps nature in a longitudinal survey of salivary bacterial communities in twins from early adolescence to early adulthood.

Authors:  Simone S Stahringer; Jose C Clemente; Robin P Corley; John Hewitt; Dan Knights; William A Walters; Rob Knight; Kenneth S Krauter
Journal:  Genome Res       Date:  2012-10-12       Impact factor: 9.043

9.  Molecular detection of multiple emerging pathogens in sputa from cystic fibrosis patients.

Authors:  Fadi Bittar; Hervé Richet; Jean-Christophe Dubus; Martine Reynaud-Gaubert; Nathalie Stremler; Jacques Sarles; Didier Raoult; Jean-Marc Rolain
Journal:  PLoS One       Date:  2008-08-06       Impact factor: 3.240

10.  Comparison of DNA extraction methods in analysis of salivary bacterial communities.

Authors:  Vladimir Lazarevic; Nadia Gaïa; Myriam Girard; Patrice François; Jacques Schrenzel
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240

View more
  50 in total

Review 1.  Lungs, microbes and the developing neonate.

Authors:  Barbara B Warner; Aaron Hamvas
Journal:  Neonatology       Date:  2015-06-05       Impact factor: 4.035

Review 2.  Past, Present, and Future Research on the Lung Microbiome in Inflammatory Airway Disease.

Authors:  Lindsay J Caverly; Yvonne J Huang; Marc A Sze
Journal:  Chest       Date:  2019-05-30       Impact factor: 9.410

Review 3.  Cystic fibrosis respiratory microbiota: unraveling complexity to inform clinical practice.

Authors:  Lindsay J Caverly; John J LiPuma
Journal:  Expert Rev Respir Med       Date:  2018-09-03       Impact factor: 3.772

4.  Airway microbiota across age and disease spectrum in cystic fibrosis.

Authors:  Edith T Zemanick; Brandie D Wagner; Charles E Robertson; Richard C Ahrens; James F Chmiel; John P Clancy; Ronald L Gibson; William T Harris; Geoffrey Kurland; Theresa A Laguna; Susanna A McColley; Karen McCoy; George Retsch-Bogart; Kurtis T Sobush; Pamela L Zeitlin; Mark J Stevens; Frank J Accurso; Scott D Sagel; J Kirk Harris
Journal:  Eur Respir J       Date:  2017-11-16       Impact factor: 16.671

5.  Understanding persistent bacterial lung infections: clinical implications informed by the biology of the microbiota and biofilms.

Authors:  Alexa A Pragman; John P Berger; Bryan J Williams
Journal:  Clin Pulm Med       Date:  2016-03

6.  Different next generation sequencing platforms produce different microbial profiles and diversity in cystic fibrosis sputum.

Authors:  Andrea Hahn; Amit Sanyal; Geovanny F Perez; Anamaris M Colberg-Poley; Joseph Campos; Mary C Rose; Marcos Pérez-Losada
Journal:  J Microbiol Methods       Date:  2016-09-05       Impact factor: 2.363

Review 7.  Biomarkers for cystic fibrosis drug development.

Authors:  Marianne S Muhlebach; J P Clancy; Sonya L Heltshe; Assem Ziady; Tom Kelley; Frank Accurso; Joseph Pilewski; Nicole Mayer-Hamblett; Elizabeth Joseloff; Scott D Sagel
Journal:  J Cyst Fibros       Date:  2016-10-27       Impact factor: 5.482

Review 8.  Methods in Lung Microbiome Research.

Authors:  Sharon M Carney; Jose C Clemente; Michael J Cox; Robert P Dickson; Yvonne J Huang; Georgios D Kitsios; Kirsten M Kloepfer; Janice M Leung; Tricia D LeVan; Philip L Molyneaux; Bethany B Moore; David N O'Dwyer; Leopoldo N Segal; Stavros Garantziotis
Journal:  Am J Respir Cell Mol Biol       Date:  2020-03       Impact factor: 6.914

9.  Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.

Authors:  J Kirk Harris; Brandie D Wagner; Edith T Zemanick; Charles E Robertson; Mark J Stevens; Sonya L Heltshe; Steven M Rowe; Scott D Sagel
Journal:  Ann Am Thorac Soc       Date:  2020-02

10.  Agmatine accumulation by Pseudomonas aeruginosa clinical isolates confers antibiotic tolerance and dampens host inflammation.

Authors:  Jennifer L McCurtain; Adam J Gilbertsen; Clayton Evert; Bryan J Williams; Ryan C Hunter
Journal:  J Med Microbiol       Date:  2019-01-22       Impact factor: 2.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.